This list contains all vaccines currently authorised in Austria (alphabetically by product name) with the following information:
- product name
- marketing authorisation holder
- target group
- possible remarks
- Adjuvant yes/no or type of adjuvant
- Thiomersal yes/no
Information on current availability and pricing as well as comparisons between different products with the same indication are not included.
The "Austrian Vaccination Plan 2021" contains all current national vaccination recommendations.
Vaccination recommendations for adults of working age
Explanations and definitions in addition to the Austrian Vaccination Plan: For the first time in Austria there are concrete vaccination recommendations for adults of working age in order to draw attention to the topic of vaccination prevention for certain occupational groups in addition to the Austrian vaccination plan.
Although the Austrian Vaccination Plan makes clear recommendations for vaccinations in adults, too low vaccination coverage rates can be observed. In order to increase this, more in-depth information and low-threshold access to the necessary vaccinations are needed. This also takes into account the WHO idea of bringing health promotion and prevention to where people live and work.
The workplace is therefore an ideal place to advise people of working age and ideally offer them local vaccination.
However, not only company doctors and occupational physicians are addressed here, but also all doctors and healthcare workers (HCWs) who provide medical care to this target group.
Special attention is given in this publication to specific occupational groups, such as social professions such as kindergarten teachers, teachers or social workers, care staff in refugee homes, emergency services, the military, people from food processing companies, hunters, foresters, farmers and veterinarians. For the latter, for example, protection against hepatitis A/B and rabies is explicitly recommended.
The chapter "Indication, Implementation and Cost Assumption" contains recommendations from the AUVA's point of view - with particular reference to the Employee Protection Act and the General Social Insurance Act. What the successful implementation of vaccination prevention in the workplace could look like is illustrated by means of a "best practice" model carried out in a large company. "Vaccinations for employees posted abroad" as well as labour law aspects (vaccination obligation, right to ask questions, duty of care, bearing of costs, etc.) are discussed in detail in separate sections.
The document "Vaccinations for adults of working age, explanations and definitions in addition to the Austrian Vaccination Plan" can be downloaded from the BMGF website.
Vaccinations for health care workers
For the first time in Austria there are concrete vaccination recommendations for employees in the health care system in order to protect not only these but above all also the patients entrusted to them from infectious diseases.
The transmission of infectious diseases in the medical field often represents an underestimated danger. This applies on the one hand to health care personnel (doctors, nurses, laboratory and cleaning staff, rescue services, civilian servants, students, home help etc.) and on the other hand above all to patients who are more susceptible to infections due to their illness. This topic was previously dealt with in the Austrian Vaccination Plan in the chapter "Vaccinations for health care personnel", but now the special requirements in the various facilities in private practice and in hospital operations are specifically and extensively dealt with.
Apart from the vaccinations recommended for all persons such as diphtheria, tetanus, whooping cough, measles, etc., for example, laboratory staff working with meningococcal isolates are advised to take appropriate prophylaxis.
As this subject area covers a variety of different aspects, experts from medical as well as ethical and legal fields were involved in the preparation of this Recommendation.
In Austria, there is no legal basis for mandatory vaccination; it is therefore all the more important to make health care workers aware of the importance of vaccination both for their own protection and that of patients in order to be able to make an informed decision - on the basis of evidence-based recommendations.
The document "Vaccinations for health care workers, recommendations as an extension of the Austrian Vaccination Plan" can be downloaded online.
Reactions and side effects after vaccinations
Uncertainties and scepticism about vaccination are primarily based on fear of side effects or damage caused by vaccination. In order to provide evidence-based information for health care professionals and patients, an addendum to the Austrian Vaccination Plan was prepared.
Hardly any other drug causes as much uncertainty and fear - sometimes unfounded - as vaccines. This is due to the fact that the vaccinated are healthy (and here primarily children) on the one hand and the large amount of misinformation in the media, especially the Internet, on the other. In order to provide the public with evidence-based information, an addendum to the Austrian Vaccination Plan was published. It deals with definitions and delimitations with regard to vaccination reactions, vaccination side effects and vaccination damage, causality assessment of vaccination side effects, the role of the drug authority as a monitoring body and excipients (in particular adjuvants). In addition, it describes how the section "Side effects" in the product information arises. These mostly very complex subject areas are explained with illustrative examples for a better understanding.
The document "Reactions and side effects after vaccinations" can be downloaded from the BMGF website.
Current recommendation of the Ministry of Health.
The annual influenza vaccination is recommended for all who want to protect themselves, but especially for the groups of people with risk factors mentioned in the recommendation:
- Children from the age of 6 years
- People with chronic diseases
- People from the age of 60
- Health and nursing staff
- Staff in community facilities (e.g. childcare facilities, schools, social institutions, etc.)
- Pregnant women and women who want to become pregnant during the influenza season
- Persons with frequent contact with the public (e.g. personnel in trade, gastronomy, tourism, etc.)
The Federal Ministry of Social Affairs, Health, Care and Consumer Protection in Austria has initiated the procurement of additional influenza vaccines for the 2020/2021 influenza season. For use in persons 65 years of age and older, the tetravalent high-dose vaccine Fluzone High-Dose Quadrivalent 2020/2021 was purchased in the US presentation which will be used primarily in old people´s and nursing homes and in individual vaccination campaigns. Until further notice, the vaccine will not be available through regular distribution channels, i.e. it will not be available through pharmacies or wholesalers.
- The English labelled influenza vaccine carries the trade name Fluzone High-Dose Quadrivalent - US presentation; brand name in the EU: Efluelda
- The imported batch is: Fluzone High-Dose Quadrivalent, packaging batch: UJ536AC - filling batch: U7084B
- No package insert or patient information leaflet in German language is enclosed with the vaccine packaged for sale. A serialization of the vaccine (i.e. the application of features on the packaging, which allows the tracing of each individual pack from the pharmacy back to the manufacturer) for the European market has also not taken place. This leads to AMVS alarms when dispensing through pharmacies.
- We offer the German translation of the US-American package insert for download on this page.
- The vaccines are delivered in packs of 10 without needles:
- No separate stickers are enclosed. Please use the removable sticker of the pre-filled syringe for documentation purposes.
- For reports of adverse reactions and complaints, please contact the local representative of the pharmaceutical company at Tel.: +43 (1) 80185-0. You can also report adverse reactions directly via the Federal Office for Safety in Health Care, Traisengasse 5, 1200 VIENNA, AUSTRIA, Fax: + 43 (0) 50 555 36207, Website: http://www.basg.gv.at/.
Recommendation Influenza Vaccination ("flu vaccination") Season 2020/2021
German translation of the US American package insert (download)
Accessible patient information (download)
The importer Valneva notified the BASG on 7.10.2020 of the shipment of the influenza vaccine FLUAD with batch number 7132B1A (registered in the UK). On 23.11.2020, Valneva informed the BASG that instead of FLUAD, the influenza vaccine named "Adjuvanted Trivalent Influenza Vaccine (TIV)" was delivered. This vaccine is qualitatively and quantitatively identical to the vaccine notified under FLUAD. The "Adjuvanted Trivalent Influenza Vaccine (TIV)" vaccine may therefore be distributed and used.
Prophylactic vaccines must be safe drugs as far as possible because, unlike therapeutic drugs, they are mostly administered to healthy people who, depending on their exposure, may only have a small risk of developing the disease without vaccination.
This results in special requirements for the so-called benefit-risk assessment of vaccines within the framework of an approval procedure. Modern vaccines are generally well tolerated due to the current production and analytical control requirements.
A vaccine is approved in Europe within the framework of EU-wide or national procedures according to a strictly regulated procedure within legal deadlines. The quality (manufacturing), safety and efficacy of a vaccine are reviewed based on preclinical and clinical data.
The official activities form a very complex safety net at all levels in the life cycle of a drug or vaccine: clinical trials, scientific advice, approval procedures, post-marketing studies required on a case-by-case basis, official inspections, batch testing and pharmacovigilance.
COVID-19 vaccines are subject to an accelerated approval process. For further information please visit the AGES website.
Before a batch of vaccine may be placed on the Austrian market, it must have been tested by an Official Medicines Control Laboratory (OMCL) of an EU/EEA Member State. The results must comply with the specifications approved in the Austrian approval. The batch production and test protocols are checked for each product batch. In addition, the submitted test samples are subjected to the prescribed analyses. The Austrian OMCL of BASG/AGES has specialised in the testing of TBE and influenza vaccines (including pandemic vaccines) in recent years.